The DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Nanoparticulate systems for brain delivery of drugs.
Abstract
The blood--brain barrier (BBB) represents an insurmountable obstacle for a large number of drugs, including antibiotics, antineoplastic agents, and a variety of central nervous system (CNS)-active drugs, especially neuropeptides. One of the possibilities to overcome this barrier is a drug delivery to the brain using nanoparticles. Drugs that have successfully been transported into the brain using this carrier include the hexapeptide dalargin, the dipeptide kytorphin, loperamide, tubocurarine, the NMDA receptor antagonist MRZ 2/576, and doxorubicin. The nanoparticles may be especially helpful for the treatment of the disseminated and very aggressive brain tumors. Intravenously injected doxorubicin-loaded polysorbate 80-coated nanoparticles were able to lead to a 40% cure in rats with intracranially transplanted glioblastomas 101/8. The mechanism of the nanoparticle-mediated transport of the drugs across the blood-brain barrier at present is not fully elucidated. The most likely mechanism is endocytosis by the endothelial cells lining the brain blood capillaries. Nanoparticle-mediated drug transport to the brain depends on the overcoating of the particles with polysorbates, especially polysorbate 80. Overcoating with these materials seems to lead to the adsorption of apolipoprotein E from blood plasma onto the nanoparticle surface. The particles then seem to mimic low density lipoprotein (LDL) particles and could interact with the LDL receptor leading to their uptake by the endothelial cells. After this the drug may be released in these cells and diffuse into the brain interior or the particles may be transcytosed. Other processes such as tight junction modulation or P-glycoprotein (Pgp) inhibition also may occur. Moreover, these mechanisms may run in parallel or may be cooperative thus enabling a drug delivery to the brain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Cordon‐Cardo, C., O’Brien, J. P., Casals, D., Rittmann-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Pitas, R. E., Boyles, J. K., Lee, S. H., Foss, D., & Mahley, R. W. (1987) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(87)90295-5 · Cited by 693
Brain drug delivery of small molecules using immunoliposomes
Huwyler, J., Wu, D., & Pardridge, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14164 · Cited by 660
An Easier, Reproducible, and Mass‐Production Method to Study the Blood–Brain Barrier In Vitro
Dehouck, M., Méresse, S., Delorme, P., Fruchart, J., & Cecchelli, R. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01236.x · Cited by 548
Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)
Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., & Aa, I. (1995) · Brain Research · doi:10.1016/0006-8993(95)00023-j · Cited by 538
Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
Gulyaev, A. E., Gelperina, S. E., Skidan, I. N., Antropov, A. S., Kivman, G. Y., & Kreuter, J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018983904537 · Cited by 521
A New Function for the LDL Receptor: Transcytosis of LDL across the Blood–Brain Barrier
Dehouck, B., Fenart, L., Dehouck, M.-P., Pierce, A., Torpier, G., & Cecchelli, R. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.4.877 · Cited by 490
Hyperalgesia Induced by Naloxone Follows Diurnal Rhythm in Responsivity to Painful Stimuli
Frederickson, R. C. A., Burgis, V., & Edwards, J. D. (1977) · Science · doi:10.1126/science.561998 · Cited by 379
Pardridge, W. M., Buciak, J. L., & Friden, P. M. (1991) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20567-5 · Cited by 358
Alyautdin, R. N., Petrov, V. E., Langer, K., Berthold, A., Kharkevich, D. A., & Kreuter, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012098005098 · Cited by 352
Research works printed but not linked: 6
- Kreuter, 1994, Nanoparticles, Vol. 10, 165
- Alyautdin, 1995, Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles, Eur. J. Pharm. Biopharm., 41, 44
- Ramge, 2000, Polysorbate 80-coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human, bovine and murine primary brain capilary endothelial cells, Eur. J. Neuro., 12, 1935
- Steiniger, 1999, The influence of polysorbate 80-coated nanoparticles on bovine brain capillary endothelial cells in vitro, Proc. Int. Symp. Control. Rel. Bioact. Mater., 26, 789
- Fenart, 1999, Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood–brain barrier, J. Pharmacol. Exp. Ther., 291, 1017
- Cecchelli, 1997, Receptor-mediated transcytosis of blood-borne molecules through blood–brain barrier endothelial cells: Drug targeting by endogenous transport routes, Proc. Intl. Symp. Control. Rel. Bioact. Mater., 24, 221
Cited by
Sorted by citations
Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Drug delivery and nanoparticles: Applications and hazards
de Jong (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s596 · Cited by 3,854
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,040
Metadata
- Authors
- Kreuter, J.
- Affiliations
- Goethe University Frankfurt (DE)
- Corresponding author
- Kreuter, Jörg
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 47
- Issue
- 1
- Pages
- 65-81
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2072229818
- Cited by
- 1,107
- References
- 50
- Citations by year
- 2026: 15 · 2025: 20 · 2024: 26 · 2023: 39 · 2022: 32 · 2021: 43 · 2020: 47 · 2019: 40 · 2018: 47 · 2017: 53 · 2016: 63 · 2015: 57 · 2014: 55 · 2013: 65 · 2012: 76
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- blood-brain barrier, nanoparticle drug delivery, brain drug delivery, apolipoprotein E, glioblastoma, doxorubicin, neuropeptides, P-glycoprotein inhibition, tight junction modulation, transcytosis, central nervous system drugs
- MeSH terms
- Animals, Antineoplastic Agents, Blood-Brain Barrier, Brain, Brain Neoplasms, Capsules, Cells, Cultured, Doxorubicin, Drug Carriers, Endothelium, Vascular, Humans, Male, Polysorbates, Surface-Active Agents, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
